Kyriakos Papadopoulos, MD
Hematology & Oncology · San Antonio, TXNPI 1376546861
Payments from drug & device makers
Across 4,517 payments — averaging $4095.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$3.4M
- AbbVie$2.1M
- Merck$2M
- Regeneron$1.8M
- Bayer$1.6M
- Daiichi Sankyo Inc.$1.3M
- plus $6.4M from 21 others
Across 85 payments — averaging $392.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$19K
- Pfizer$7K
- Eli Lilly$7K
- AbbVie$85
What the payments were for
- Food & beverage$737100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 2,323 | $3,427,043 |
| AbbVie | 779 | $2,075,367 |
| Merck | 74 | $1,956,290 |
| Regeneron | 267 | $1,800,651 |
| Bayer | 153 | $1,593,237 |
| Daiichi Sankyo Inc. | 203 | $1,258,280 |
| Biontech SE | 172 | $991,289 |
| Daiichi Sankyo Company LTD | 94 | $909,753 |
| AstraZeneca | 9 | $818,665 |
| Pfizer | 66 | $718,045 |
| Mirati Therapeutics, Inc. | 134 | $542,605 |
| Genmab A/s | 140 | $538,482 |
| Eli Lilly | 7 | $435,984 |
| E.r. Squibb & Sons, L.L.C. | 6 | $433,156 |
| Astrazeneca UK Limited | 2 | $415,540 |
| Amgen | 18 | $389,495 |
| EMD Serono, Inc. | 19 | $85,709 |
| Alnylam Pharmaceuticals Inc. | 16 | $79,560 |
| ADC Therapeutics America, Inc. | 21 | $31,276 |
| Bristol Myers Squibb | 6 | $173 |
| Tempus AI, Inc | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
How this compares
$18,500,740 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 11 | $164,982 |
| Abiraterone Acetate | 12 | $1,578 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $521 |
| Lidocaine Hcl ViscousLidocaine Hcl | 12 | $104 |
| Prednisone | 17 | $41 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in San Antonio
- Drew RascoSan Antonio$14.1M
- David SommerhalderSan Antonio$10.4M
- Emmalind AponteSan Antonio$4.4M
- Manuel SantiagoSan Antonio$3.9M
- Paul ShaughnessySan Antonio$3.7M
- Ildefonso Rodriguez RiveraSan Antonio$2.7M
- Sharon WilksSan Antonio$2.5M
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.